These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Mel D; Gangarosa EJ; Radovanovic ML; Arsic BL; Litvinjenko S Bull World Health Organ; 1971; 45(4):457-64. PubMed ID: 4948417 [TBL] [Abstract][Full Text] [Related]
3. Studies on virulence of Shigella flexneri. Protective effect of outer membrane proteins. Mulczyk M; Adamus G; Witkowska D; Romanowska E Arch Immunol Ther Exp (Warsz); 1981; 29(1):85-90. PubMed ID: 7025793 [TBL] [Abstract][Full Text] [Related]
4. The cellular and humoral immune response after administration to the guinea pig of Shigella flexneri 2a T32--Istrati vaccinal strain by different routes. Meitert T; Radu I; Ciudin L; Pencu E; Tonciu M Arch Roum Pathol Exp Microbiol; 1978; 37(3-4):267-76. PubMed ID: 395927 [No Abstract] [Full Text] [Related]
5. Efficacy of a polyvalent protein-polysaccharide dysentery oral vaccine. Zhang HM; Li YP; Song LH; Yu XL; Liu NH; Kong XE; Li L; Zhai YL Chin Med J (Engl); 1987 May; 100(5):425-8. PubMed ID: 3115716 [No Abstract] [Full Text] [Related]
15. Construction of a stable and non-resistant bivalent vaccine candidate strain against Shigella flexneri 2a and Shigella sonnei. Rui X; Xu Y; Wan H; Su G; Huang C Chin J Biotechnol; 1996; 12(2):89-97. PubMed ID: 8988355 [TBL] [Abstract][Full Text] [Related]
16. Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen. Formal SB; Hale TL; Kapfer C; Cogan JP; Snoy PJ; Chung R; Wingfield ME; Elisberg BL; Baron LS Infect Immun; 1984 Nov; 46(2):465-9. PubMed ID: 6389344 [TBL] [Abstract][Full Text] [Related]
17. Auxotrophic live oral Shigella flexneri vaccine protects monkeys against challenge with S. flexneri of different serotypes. Kärnell A; Sweiha H; Lindberg AA Vaccine; 1992; 10(3):167-74. PubMed ID: 1557932 [TBL] [Abstract][Full Text] [Related]
18. Vaccine potential for inactivated shigellae. Osorio M; Bray MD; Walker RI Vaccine; 2007 Feb; 25(9):1581-92. PubMed ID: 17178431 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R; Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770 [TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]